Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Current Opinion in Hematology|December 18, 2004
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challengesDavid W Sternberg, Jonathan D Licht
Hematology. American Society of Hematology. Education Program|November 24, 2005
The molecular pathology of acute myeloid leukemiaJonathan D Licht, David W Sternberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
The role of signal transducer and activator of transcription factors in leukemogenesisDavid W Sternberg, D Gary Gilliland
Experimental Cell Research|July 24, 2007
Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell contextMaria A Theodoraki, Mary Kunjappu, David W Sternberg, et al.
Molecular & Cellular Proteomics : MCP|April 26, 2005
Quantitative proteomic analysis using isobaric protein tags enables rapid comparison of changes in transcript and protein levels in transformed cellsRichard D Unwin, Andrew Pierce, Rod B Watson, et al.
The Journal of Biological Chemistry|December 1, 2004
Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABLRichard D Unwin, David W Sternberg, Yuning Lu, et al.
Blood|February 14, 2004
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3aTing-Lei Gu, Zuzana Tothova, Blanca Scheijen, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2004
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKsM Golam Mohi, Christina Boulton, Ting-Lei Gu, et al.
Future Oncology (London, England)|December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKITony Mok, Pasi A Jänne, Makoto Nishio, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
Pageof 2